Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results

Conclusions Long-term enzalutamide monotherapy in men with noncastrate HNPC is associated with large sustained reductions in PSA, signals indicating a favorable tumor response, and favorable safety/tolerability profile, with relatively small negative effects on total-body BMD. Patient summary In this long-term follow-up of the efficacy and safety of enzalutamide monotherapy in patients with hormone-naïve prostate cancer, enzalutamide maintained long-term reductions in prostate-specific antigen, with a minimal impact on total-body bone mineral density. Trial registration NCT01302041 Long-term enzalutamide monotherapy for up to 2 yr in men with noncastrate hormone-naïve prostate cancer is associated with large, sustained reductions in prostate-specific antigen, signals indicating a favorable tumor response, and favorable tolerability, with minimal negative effects on total body bone mineral density.
Source: European Urology - Category: Urology & Nephrology Source Type: research